You are here:

Griphingo Pharmaceuticals

Back to overview

Groningen-based Griphingo Pharmaceuticals conducts applied research into the development of an innovative inhalation therapy for COPD patients. For the development of this therapy, the start-up works with a network of COPD and medicine development experts from the Northern region.

Current COPD treatment is not effective enough to suppress the inflammatory reactions in the lungs of COPD patients and also has many side effects. Griphingo hopes to curb these inflammatory reactions with a new molecule, which has an alternative target compared to existing medication, in order to significantly improve the quality of life of COPD patients. In the coming period, Griphingo will focus on optimising the molecules in collaboration with Symeres and testing efficacy in collaboration with Aquilo.

Griphingo Pharmaceuticals belongs to the fund:

Pharma Connect Capital">

Investment fund Pharma Connect Capital (PCC) invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects...

View all the funds from the IFG

Cottonwood Technology Fund is an early stage fund that invests in deeptech/hard science startups with patented disruptiv...


CapitalT is a (pre-)seed fund that invests in companies which use AI to solve real world problems in climate tech, educa...